Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 173 resultados

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

EBRAINS 2.0: EBRAINS 2.0 A Research Infrastructure to Advance Neuroscience and Brain Health UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-INFRA-2022-SERV-B-01 EBRAINS is a collaborative European Research Infrastructure designed to advance and accelerate progress in neuroscience and brain health. Th...
2023-12-14 - 2026-12-31 | Financiado

DRESSCODE: Engineering next-generation fusion proteins to dress the cell membrane with functionally enhanced re... UNIVERSITAETSKLINIKUM FREIBURG tramitó un HORIZON EUROPE: ERC-2023-STG No drug can be effective without an appropriate delivery system; this is why the development of formulations for effective and safe drug del...
2023-10-18 - 2028-12-31 | Financiado

AlloCure: Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapse UNIVERSITAETSKLINIKUM FREIBURG tramitó un HORIZON EUROPE: ERC-2022-ADG Acute graft-versus-host disease (GVHD) and leukemia relapse cause 75% of the mortality of patients having undergone allogeneic hematopoietic...
2023-06-19 - 2028-09-30 | Financiado

STIC-GBM: Spatio-temporal dynamics of immune circuitry in glioblastoma: from single cells to comprehensive mod... UNIVERSITAETSKLINIKUM FREIBURG tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Glioblastoma (GBM) is the most lethal brain malignancy in adults and is associated with a poor prognosis. Therapy options in GBM patients ar...
2023-03-23 - 2026-03-31 | Financiado

THOR: building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology fo... UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 Tenths of millions of people with organ failures or suffering from degenerative diseases are waiting for a novel cellular therapy or for a t...
2022-12-22 - 2026-12-31 | Financiado

ERA4Health: Fostering a European Research Area for Health Research UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-03 Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collabo...
2022-11-25 - 2029-10-31 | Financiado

UPSIDE: Focused Ultrasound Personalized Therapy for the Treatment of Depression (UPSIDE) UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting 300 million people with a lifetime prevalence of 15%...
2022-06-23 - 2026-08-31 | Financiado

geneTIGA: Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome edit... UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 "There is an increasing prevalence of chronic diseases caused by undesired immune reactions (>10%) with high burden for the both patients (c...
2022-05-23 - 2026-06-30 | Financiado

NEXUS: automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS UNIVERSITAETSKLINIKUM FREIBURG participó en un HORIZON EUROPE: HORIZON-EIC-2021-TRANSITIONOPEN-01 The NEXUS project will develop an easily customizable integrated platform to enable Extracellular Vesicles (EVs) separation, purification an...
2022-05-19 - 2025-05-31 | Financiado

SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol... UNIVERSITAETSKLINIKUM FREIBURG participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado

IMMUNOSTIM: Novel small molecule activators of the NLRP3 inflammasome as immunostimulants UNIVERSITAETSKLINIKUM FREIBURG tramitó un H2020: ERC-2020-PoC We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome. The goal of this project is to determine th...
2021-08-26 - 2023-02-28 | Financiado

milieuPCa: Defining the immunosuppressive milieu of prostate cancer with single cell Omics technologies UNIVERSITAETSKLINIKUM FREIBURG tramitó un H2020: H2020-MSCA-IF-2020 The immune contexture of prostate cancer is poorly studied, despite among researchers there is a strong interest in developing immunotherapy...
2021-03-09 - 2025-12-29 | Financiado

SOL: Switchable rhodOpsins in Life Sciences UNIVERSITAETSKLINIKUM FREIBURG participó en un H2020: ERC-2020-SyG Bistable rhodopsins are naturally photosensitive G-protein coupled receptors (GPCRs) that can be toggled between stable ON and OFF states us...
2021-02-07 - 2028-08-31 | Financiado

EuroGCT: European consortium for communicating gene and cell based therapy information. UNIVERSITAETSKLINIKUM FREIBURG participó en un H2020: H2020-SC1-BHC-2018-2020 The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organisations and institutions acros...
2021-01-25 - 2026-01-31 | Financiado

UKLFR